Profile change history

What changed for CJC-1295?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed CJC-1295 identity.

12Total events
10Record additions
2Version changes
8Cited source years

Before and after

Preserved version changes

Profile updated

CJC-1295 profile

We added a plain-language reader guide with cited answers, re-checked FDA’s CJC-1295 evaluation and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include CJC-1295.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Profile summary

Before
FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.
After
A synthetic GHRH analogue that is not FDA-approved. FDA treats CJC-1295 and CJC-1295 with DAC as distinct substances and found only small, short studies in healthy adults.

Evidence note

Before
FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.
After
FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.

Cited source records

Before
fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024
After
fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024, federal-register-2024-24828-d546fa8a5f55, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

Named organizations

Before
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]
After
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

Claim citations

Before
name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024
After
name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024, fda-bulk-peptide-risks, hhs-503a-peptide-enforcement-discretion-policy-2026
Correction

CJC-1295 profile

We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form.

PeptideScanner change date
September 15, 2026
Evidence lane
Profile

Profile summary

Before
A peptide named in FDA compounding-risk and DOJ enforcement records.
After
FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.

Evidence note

Before
FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.
After
FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.

Cited source records

Before
fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement
After
fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement, fda-cjc-1295-briefing-2024

Claim citations

Before
name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; evidenceNote: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement
After
name: doj-unapproved-peptide-enforcement; aliases: fda-bulk-peptide-risks; category: fda-bulk-peptide-risks, doj-unapproved-peptide-enforcement; status: doj-unapproved-peptide-enforcement; summary: fda-cjc-1295-briefing-2024; evidenceNote: fda-cjc-1295-briefing-2024

Collection chronology

Evidence added to PeptideScanner

Browse all 10 connected records →

Showing the latest 10 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 14, 2026.

Record added

Detection of CJC-1295 in Equine Plasma by ELISA.

PubMed lists PMID 42876013 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-14 (day precision). PeptideScanner associated the retained record with the identity slug cjc-1295. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 15, 2026
Evidence lane
Literature metadata
Record added

Federal Register notice 2024-24828

The Federal Register published notice 2024-24828, attributed to FDA and its parent HHS department, on 2024-10-25. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to CJC-1295.

PeptideScanner change date
August 21, 2026
Cited source date
October 25, 2024
Evidence lane
Regulatory
Record added

PubMed record PMID 17018654

PeptideScanner retained PubMed bibliographic metadata for PMID 17018654 at 2026-07-30T21:09:06.872Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2006-10-05. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
December 1, 2018
Evidence lane
Literature metadata
Record added

PubMed record PMID 19386527

PeptideScanner retained PubMed bibliographic metadata for PMID 19386527 at 2026-07-30T18:28:26.873Z. PubMed recorded a metadata revision date of 2025-05-29 and an Entrez history date of 2009-04-24. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
May 29, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 30489688

PeptideScanner retained PubMed bibliographic metadata for PMID 30489688 at 2026-07-30T20:43:12.045Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2018-11-30. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
December 10, 2019
Evidence lane
Literature metadata
Record added

PubMed record PMID 30938069

PeptideScanner retained PubMed bibliographic metadata for PMID 30938069 at 2026-07-30T20:34:12.987Z. PubMed recorded a metadata revision date of 2020-01-13 and an Entrez history date of 2019-04-03. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
January 13, 2020
Evidence lane
Literature metadata
Record added

PubMed record PMID 15817669

PeptideScanner retained PubMed bibliographic metadata for PMID 15817669 at 2026-07-30T22:26:16.765Z. PubMed recorded a metadata revision date of 2010-11-18 and an Entrez history date of 2005-04-09. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
November 18, 2010
Evidence lane
Literature metadata
Record added

PubMed record PMID 16352683

PeptideScanner retained PubMed bibliographic metadata for PMID 16352683 at 2026-07-30T21:09:05.761Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2005-12-15. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
December 1, 2018
Evidence lane
Literature metadata
Record added

PubMed record PMID 21204297

PeptideScanner retained PubMed bibliographic metadata for PMID 21204297 at 2026-07-30T21:38:23.138Z. PubMed recorded a metadata revision date of 2016-05-11 and an Entrez history date of 2011-01-05. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
May 11, 2016
Evidence lane
Literature metadata
Record added

PubMed record PMID 26771670

PeptideScanner retained PubMed bibliographic metadata for PMID 26771670 at 2026-07-30T21:35:57.020Z. PubMed recorded a metadata revision date of 2016-12-30 and an Entrez history date of 2016-01-16. PeptideScanner associated this retained record with the identity slug cjc-1295. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
December 30, 2016
Evidence lane
Literature metadata